🇺🇸 FDA
Patent

US 11279934

Methods for treating cancer using nucleic acids targeting MDM2 or MYCN

granted A61PA61P27/02A61P35/00

Quick answer

US patent 11279934 (Methods for treating cancer using nucleic acids targeting MDM2 or MYCN) held by Phio Pharmaceuticals Corp. expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Phio Pharmaceuticals Corp.
Grant date
Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61P, A61P27/02, A61P35/00